• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email
    SC 13G/A 1 p24-3227sc13ga.htm ABEONA THERAPEUTICS INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Abeona Therapeutics Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    00289Y206

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    CUSIP No. 00289Y20613G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    888,870 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    888,870 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    888,870 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 00289Y20613G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    888,870 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    888,870 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    888,870 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 00289Y20613G/APage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    888,870 shares of Common Stock issuable upon exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    888,870 shares of Common Stock issuable upon exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    888,870 shares of Common Stock issuable upon exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 00289Y20613G/APage 5 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
      Abeona Therapeutics Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.01 per share (“Common Stock”), of the Issuer held by (and underlying warrants held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Common Stock held by (and underlying warrants held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.01 per share.

     

    Item 2(e). CUSIP Number.
      00289Y206

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on September 30, 2024.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.  Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.   The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

     

     

    CUSIP No. 00289Y20613G/APage 6 of 7 Pages

      

      The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person is based on 44,203,267 shares of Common Stock outstanding, which is the sum of: (i) 43,314,397 shares of Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024; and (ii) 888,870 warrant shares exercised as reported herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      See Item 2(a).

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 00289Y20613G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

      STEVEN A. COHEN
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO

    DatePrice TargetRatingAnalyst
    6/2/2025$19.00Outperform
    Oppenheimer
    3/5/2025$16.00Outperform
    Oppenheimer
    7/3/2024$15.00Buy
    H.C. Wainwright
    5/30/2024$21.00Buy
    Stifel
    11/30/2021$5.00 → $1.00Outperform → Market Perform
    SVB Leerink
    11/29/2021$5.00 → $4.00Buy
    HC Wainwright & Co.
    7/19/2021$8.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ABEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On March 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,400 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the

    4/6/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

    CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. "Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as our fifth QTC significantly expands patient access to ZEVASKYN in the New York metropolitan area and across the Northeast," said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. "Partnering with an institution recognized globally for its leadership in genetic medicines a

    4/2/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    SEC Filings

    View All

    Abeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    4/7/26 8:35:30 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Abeona Therapeutics Inc.

    SCHEDULE 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    3/26/26 9:02:29 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    3/20/26 4:30:37 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Abeona Therapeutics with a new price target

    Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00

    6/2/25 8:44:24 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Abeona Therapeutics with a new price target

    Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00

    3/5/25 7:50:58 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Abeona Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $15.00

    7/3/24 7:23:46 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Goldan Keith A.

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/7/26 8:47:16 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Goldan Keith A.

    3 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/7/26 8:45:26 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Seshadri Vishwas

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    3/31/26 9:03:36 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Alland Leila bought $51,799 worth of shares (11,000 units at $4.71), increasing direct ownership by 15% to 82,857 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    5/20/24 8:30:14 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seshadri Vishwas bought $32,000 worth of shares (10,000 units at $3.20), increasing direct ownership by 2% to 538,260 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/29/24 8:30:16 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Charles Faith L. bought $24,764 worth of shares (7,550 units at $3.28), increasing direct ownership by 11% to 78,323 units (SEC Form 4)

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/29/24 8:30:14 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Leadership Updates

    Live Leadership Updates

    View All

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

    CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. "Mohamad brings a wealth of experience in strategic planning and business development," said Vish Seshadri, Chief Executive Officer of Abeona. "We look forward to leveraging his extensive network and proven expertise to optimize our operations and guide Abeona toward value-creating partnerships." Mr. Tabrizi transitions to Abeon

    12/15/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

    CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."

    10/20/25 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    10/8/24 4:29:58 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abeona Therapeutics Inc. (Amendment)

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    6/3/24 4:30:14 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    Financials

    Live finance-specific insights

    View All

    Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

    - First ZEVASKYN® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the full year of 2025 and recent operational progress. "2026 is about building a steady cadence of biopsies and treatments," said Vish Seshadri, Chief Executive Officer of Abeona. "We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us

    3/17/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

    CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will b

    3/3/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

    - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the third quarter of 2025 and shared recent operational progress. "We are scaling the ZEVASKYN launch to meet patient needs

    11/12/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care